II конгресс сердечно-сосудистых хирургов
                   и интервенционных радиологов
     Северо-Западного федерального округа

Чрескожные вмешательства vs медикаментозная терапия

The Truth and Consequences of the COURAGE Trial
2007 г.
Dean J. Kereiakes, MD, FACC, Paul S. Teirstein, MD, FACC, Ian J. Sarembock, MB, CHB, MD, David R. Holmes, JR, MD, Mitchell W. Krucoff, MD, FACC, William W. O’Neill, MD, Ron Waksman, MD, FACC, David O. Williams, MD, Jeffrey J. Popma, MD, FACC, Maurice Buchbinder, MD, FACC, Roxana Mehran, MD, Ian T. Meredith, MBBS, PHD, FACC, Jeffrey W. Moses, MD, FACC, Gregg W. Stone, MD, FACC
Since the introduction of coronary balloon angioplasty by Gruentzig in 1977, significant evolution has occurred in both catheter-based percutaneous coronary intervention (PCI) as well as adjunctive pharmacotherapies.

Does Preventive PCI Work?
2007 г.
Judith S. Hochman, M.D., and P. Gabriel Steg, M.D.
Treatments are designed to make people feel better or live longer. Percutaneous coronary intervention (PCI) is effective at reducing angina in patients with symptomatic coronary artery disease and at reducing mortality in patients who have acute myocardial infarction with ST-segment elevation and in those who have high-risk acute coronary syndromes without ST-segment elevation.

Optimal Medical Therapy with or without PCI for Stable Coronary Disease
2007 г.
William E. Boden, M.D., Robert A. O’Rourke, M.D., Koon K. Teo, M.B., B.Ch., Ph.D., Pamela M. Hartigan, Ph.D., David J. Maron, M.D., William J. Kostuk, M.D., Merril Knudtson, M.D., Marcin Dada, M.D., Paul Casperson, Ph.D., Crystal L. Harris, Pharm.D., Bernard R. Chaitman, M.D., Leslee Shaw, Ph.D., Gilbert Gosselin, M.D., Shah Nawaz, M.D., Lawrence M. Title, M.D., Gerald Gau, M.D., Alvin S. Blaustein, M.D., David C. Booth, M.D., Eric R. Bates, M.D., John A. Spertus, M.D., M.P.H., Daniel S. Berman, M.D., G.B. John Mancini, M.D., and William S. Weintraub, M.D., for the COURAGE Trial Research Group
During the past 30 years, the use of percutaneous coronary intervention (PCI) has become common in the initial management strategy for patients with stable coronary artery disease in North America, even though treatment guidelines advocate an initial approach with intensive medical therapy, a reduction of risk factors, and lifestyle intervention (known as optimal medical therapy).

Survival After Coronary Revascularization in the Elderly
2010 г.
Michelle M. Graham, MD; William A. Ghali, MD, MPH; Peter D. Faris, PhD; P. Diane Galbraith, BN; Colleen M. Norris, PhD; Merril L. Knudtson, MD; for the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators
Cardiovascular disease is a leading cause of morbidity and mortality in older people, and increasingly, elderly patients are referred for revascularization.